JNJ-88549968 clinical trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.